[Effect of proteasome inhibitors MG-132 at different doses on cultured K562 cell apoptosis]

Qing-Wen Shao1, Tian-Yang Xue, Ji-Zhao Gao

  • 1Department of Pediatrics, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangshu Province, China.

Insights

Proteasome inhibitor MG-132 induces K562 cell apoptosis and proliferation inhibition in a dose-dependent manner. This occurs through decreased NF-kappaB activity and increased glucocorticoid receptor (GR) expression.

Area of Science:

  • Cell Biology
  • Pharmacology
  • Cancer Research

Background:

  • K562 cells are a human chronic myeloid leukemia cell line.
  • Proteasome inhibitors are a class of drugs that block proteasome activity.
  • NF-kappaB and glucocorticoid receptor (GR) play roles in cell survival and apoptosis.

Purpose of the Study:

  • To investigate the effects of proteasome inhibitor MG-132 on K562 cell apoptosis.
  • To determine the dose-dependent relationship of MG-132's effects.
  • To examine the impact of MG-132 on NF-kappaB activity and GR expression.

Main Methods:

  • MTT assay for cell proliferation inhibition.
  • Immunocytochemistry for NF-kappaB activity and GR expression.
  • Flow cytometry for K562 cell apoptosis analysis.

Main Results:

  • MG-132 demonstrated a dose-dependent inhibition of K562 cell proliferation.
  • NF-kappaB activity decreased, while GR expression increased with higher MG-132 doses.
  • K562 cell apoptosis rates significantly increased in a dose-dependent manner with MG-132 treatment.

Conclusions:

  • MG-132 induces K562 cell apoptosis and proliferation inhibition.
  • These effects are mediated by a dose-dependent down-regulation of NF-kappaB activity and up-regulation of GR expression.
  • MG-132 shows potential as a therapeutic agent for K562 leukemia.